# PT-141 FAQ: Bremelanotide Questions Answered From the Record

> PT-141 (bremelanotide) FAQ: what it is, how it works, the approved dose, side effects, and access — answered directly from the published research and the FDA label, each cited.

Direct, cited answers to the most common bremelanotide questions — mechanism, dosing, status, and access.

## Can you get PT-141 through telehealth?

The approved drug, bremelanotide, is a prescription medicine, so access goes through a prescriber. Published reviews describe telemedicine workflows for sexual-medicine patients and document broad adoption of remote sexual-medicine care across countries [8][15]. This site does not connect anyone to a prescriber or dispense anything; it summarizes that context.

## What is PT-141?

PT-141 (bremelanotide) is a synthetic alpha-MSH analogue that activates melanocortin receptors (MC3R/MC4R) in the central nervous system [1]. In rats, nonhuman primates, and men with erectile dysfunction it produced dose-dependent erectile activity and activated hypothalamic neurons, consistent with a brain-centered mechanism [1].

## What is PT-141 peptide?

The PT-141 peptide is a synthetic cyclic heptapeptide — a ring of seven amino acids — that mimics alpha-MSH and activates central MC3R/MC4R melanocortin receptors [1]. Its cyclic lactam structure makes it more stable than linear melanocortin peptides, and only the prescription product carries an FDA approval [1][7].

## What does the PT-141 peptide do?

It activates melanocortin receptors (MC3R/MC4R) in the brain, engaging circuits tied to sexual desire [1]. In premenopausal women with HSDD it improved sexual desire and reduced desire-related distress in two Phase 3 trials [3]. It does not act on blood vessels the way erectile-dysfunction pills do [1].

## What is PT-141 used for?

The only FDA-approved use is acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [7][9]. Every other use — in men, postmenopausal women, for erectile dysfunction, or for performance — is off-label or investigational, with weaker or no controlled evidence [9].

## Is PT-141 the same as bremelanotide?

Yes. "PT-141" is the development code and "bremelanotide" is the international nonproprietary name (INN) for the same melanocortin receptor agonist [1][7]. The approved prescription product is the regulated version; powder sold as "PT-141" research chemical is the same molecule in name only, without oversight of identity or purity.

## What is bremelanotide?

Bremelanotide is the generic (INN) name for PT-141, a melanocortin (MC3R/MC4R) receptor agonist [1]. It was FDA-approved on June 21, 2019 (NDA 210557) for acquired, generalized HSDD in premenopausal women, given as a 1.75 mg subcutaneous as-needed injection [7].

## How does PT-141 work?

It activates MC4R (and MC3R) melanocortin receptors concentrated in the hypothalamus and limbic system, engaging dopamine pathways that govern sexual desire [1]. A 2022 fMRI study in women with HSDD showed MC4R agonism raised desire for up to 24 hours and altered brain processing of erotic cues [5].

## What receptors does PT-141 act on?

PT-141 is an agonist at melanocortin receptors, chiefly MC4R, with MC3R as a secondary central target [1]. These are central-nervous-system receptors concentrated in the hypothalamus and limbic system; MC1R activation in skin underlies the pigmentation effect seen with repeated dosing [1][7].

## Does PT-141 work through the brain or through blood flow?

Through the brain. PT-141 acts centrally on MC4R/MC3R circuits governing sexual motivation, unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle to improve blood flow [1]. A 2022 fMRI study directly showed altered central brain processing after MC4R agonism [5].

## What is a melanocortin receptor agonist?

A melanocortin receptor agonist is a molecule that activates the melanocortin receptor family (MC1R-MC5R), which normally respond to peptides like alpha-MSH [1]. PT-141 is a synthetic agonist targeting the central MC3R and MC4R subtypes involved in sexual desire and appetite [1].

## Does PT-141 increase testosterone?

No. PT-141 does not act through the hypothalamic-pituitary-gonadal axis and does not directly raise testosterone; it acts on central melanocortin receptors governing desire [1]. This is a common misconception — its mechanism is neural, not hormonal in the testosterone sense.

## How is PT-141 different from PDE-5 inhibitors?

PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow, while PT-141 acts centrally on brain melanocortin receptors that govern sexual desire and motivation [1]. They target entirely different mechanisms — blood flow versus the neural circuitry of desire.

## What is the PT-141 dosage?

The approved dosage for bremelanotide is 1.75 mg subcutaneously, as needed, no more than once per 24 hours and no more than eight doses per month, per the US prescribing information [7]. This is the labeled regimen for premenopausal HSDD; this site recommends no dose to anyone.

## How much PT-141 should I take?

This site does not recommend a dose. The FDA label documents an approved 1.75 mg subcutaneous as-needed regimen for premenopausal women with HSDD, with a ceiling of one dose per 24 hours and eight per month [7]. Any decision about a prescription medicine belongs with a qualified prescriber, not a website.

## How much PT-141 to inject?

The labeled subcutaneous dose for the approved product is 1.75 mg as needed [7]. This is reported as a label figure, not a recommendation. The research-chemical form has no verified concentration, so a label dose says nothing about what is in such a vial; this site provides no injection instructions.

## What is the PT-141 dosage for women?

In female-rat models, PT-141 selectively stimulated appetitive solicitational sexual behaviors without affecting lordosis, pacing, or motor activity, indicating central melanocortin systems regulate female desire [2]. Clinically, the approved 1.75 mg subcutaneous as-needed regimen applies specifically to premenopausal women with HSDD [7][9].

## How do you reconstitute PT-141?

The approved bremelanotide product is supplied as a ready-to-use prefilled subcutaneous injection per its prescribing information, not a powder the user reconstitutes [7]. This site does not provide reconstitution instructions for non-pharmaceutical research-chemical material, whose identity and purity are unverified.

## How do you take PT-141?

The approved product is given as a 1.75 mg subcutaneous injection, as needed, at least 45 minutes before anticipated activity, per the label [7]. This is a description of the labeled regimen, not an instruction; decisions about a prescription drug belong with a prescriber.

## How often can you take PT-141?

The label caps the approved product at no more than one dose per 24 hours and no more than eight doses per month [7]. In the 52-week open-label extension, sustained dosing produced no new safety signals, with nausea (40.4%) the leading drug-related effect [4].

## What is the approved bremelanotide dose?

1.75 mg subcutaneously, as needed, for acquired, generalized HSDD in premenopausal women — no more than once per 24 hours and no more than eight times per month, per the US prescribing information [7]. This is the dose carried from the Phase 3 RECONNECT trials into the label [3].

## How long does PT-141 last?

The terminal half-life of the approved product is approximately 2.7 hours (range 1.9-4.0 h) after subcutaneous injection, with peak levels around 0.5-1.0 hour [7]. Separately, a 2022 fMRI study found the effect on brain processing of desire persisted for up to 24 hours, longer than the drug stays in the blood [5][7].

---

A regulatory-careful console on the PT-141 (bremelanotide) record — the one approved use (premenopausal HSDD) held apart from the off-label edges and the no-oversight research-chemical form, every figure logged to the trials or the FDA label and nothing here prescribed, dispensed, or sold from behind the steel.